Pentetreotide
Phase 2Peptide
Pentetreotide is one of 7 small molecule programs targeting Cushing syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Cushing Syndrome
#DrugCompanyPhaseTrials
1Signifor
RRECORDATI GROUP
Approved
Mifeprex
DDanco
Approved
Nizoral
WWim Janssens
Approved
Lifyorli (copackaged)
CCorcept Therapeutics
Phase 3
Cialis
Eli LillyPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Pentetreotide
EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cushing syndrome1 trial
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00001849·95 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pentetreotide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details